London, June 12, 2026, 15:05 BST
- Haleon shares in London edged up near 336p, staying below the 52-week high they hit in February.
- Haleon’s India move is the new focus. The company is betting on long-term growth here, but this won’t have a big impact on earnings until later this decade.
Haleon PLC picked up 0.60% in London on Friday, trading at 336.00p at 3:00 p.m. after starting the session at 332.30p. Shares moved in a 331.40p to 337.40p range, according to Google Finance. Investors looked at Haleon’s new India manufacturing initiative alongside signs of slower growth in some of its consumer health lines. The price stayed under the 52-week high of 416.10p. The price-to-earnings ratio hovered around 18.
Haleon shares are moving as the company keeps working to show investors it can speed up growth after its slow start since splitting from GSK. The company behind Sensodyne, Panadol, Advil and Centrum reported in April that first-quarter organic revenue rose 2.2%. That’s with price up 2.4% and volume off 0.2%. Oral Health led the way, up 8.3%. Respiratory Health dropped 3.4% after a soft cold and flu season.
India is now in focus as a growth market. Haleon plans to spend around £175 million building a new oral-health plant in Madhya Pradesh and boost rural distribution, saying it wants to reach more than three million outlets by 2030. Business Standard, citing a PRNewswire release Thursday night, reported the new Pithampur plant would be Haleon’s first in India, span over 40 acres, and help meet both local demand and exports in Asia.
Haleon CEO Brian McNamara called the project a “strategic growth investment,” telling reporters that “India is a key strategic market for Haleon and an important driver of our long-term growth.” Haleon says the move strengthens its bull case, with India being one of its fastest-growing markets and oral health its top category recently. Still, the timeline is slow. The company’s statement pegs the site’s opening for early 2028. Supply follows in 2029, so it’s a longer-term boost to value, not an immediate lift to earnings. Haleon Corporate
Shareholder returns are also part of the support for the stock. Haleon has set aside £500 million for share buybacks in 2026, and an Investegate regulatory filing out this week showed the company bought 16,585,448 ordinary shares for cancellation from June 1 to June 4 under the buyback programme. Buybacks can lift earnings per share by cutting the share count, but they don’t resolve weak revenue growth on their own.
Haleon’s next big event is its first-half 2026 results on July 30. Investors are looking to see if management can push closer to full-year targets of 3% to 5% organic revenue growth and high-single-digit adjusted operating profit growth at constant currency. North America demand, recovery after the soft cold and flu season, Oral Health trends, and whether productivity savings hold up for margins are the main things to watch.
The stock isn’t obviously cheap anymore and looks more or less fairly valued. Bulls point to the defensive profile in healthcare brands, Indian and emerging-market growth, Oral Health gains, a dividend yield above 2%, and buybacks. Bears flag that Q1 was driven by pricing, with slightly negative volume, softer Respiratory Health, and say the new India plant needs years before it matters. Analyst views remain mostly constructive—Google Finance lists seven buys, two holds, and one sell on the London listing, but the spread between the top and bottom 12-month targets suggests execution risk is still a factor.
